LENZ

LENZ Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Versant Venture Capital VI, L.P.10 Percent Owner
$10M350k shares
SellJun 10, 2025
$29.00
--
Versant Venture Capital VI, L.P.10 Percent Owner
$3.1M100.9k shares
SellJun 20, 2025
$30.35
--
Versant Venture Capital VI, L.P.10 Percent Owner
$3.0M100k shares
SellJun 18, 2025
$29.95
--
Versant Venture Capital VI, L.P.10 Percent Owner
$4.1M133.9k shares
SellJun 20, 2025
$30.25
--
Versant Venture Capital VI, L.P.10 Percent Owner
$6.1M200k shares
SellJun 27, 2025
$30.47
--
Versant Venture Capital VI, L.P.10 Percent Owner
$6.5M191.4k shares
SellJul 10, 2025
$34.00
--

News

proactiveinvestors.comLENZ Therapeutics adds China partner for presbyopia drug VIZZproactiveinvestors.comJun 8globenewswire.comLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater Chinaglobenewswire.comJun 7globenewswire.comLENZ Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.comMay 26247wallst.comHere Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More247wallst.comMay 12seekingalpha.comLENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 11